Last reviewed · How we verify

CTI BioPharma — Portfolio Competitive Intelligence Brief

CTI BioPharma pipeline: 0 marketed, 0 filed, 3 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 4 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Pixantrone + Rituximab Pixantrone + Rituximab phase 3 Topoisomerase II inhibitor + monoclonal antibody combination Topoisomerase II (pixantrone); CD20 (rituximab) Oncology
pixantrone, cyclophosphamide, vincristine, rituximab, prednisone pixantrone, cyclophosphamide, vincristine, rituximab, prednisone phase 3 anthracycline DNA Oncology
Gemcitabine + Rituximab Gemcitabine + Rituximab phase 3 Chemotherapy + monoclonal antibody combination Ribonucleotide reductase (gemcitabine); CD20 (rituximab) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 2 shared drug classes
  2. AstraZeneca · 2 shared drug classes
  3. AbbVie Inc. · 1 shared drug class
  4. Addpharma Inc. · 1 shared drug class
  5. Aevi Genomic Medicine, LLC, a Cerecor company · 1 shared drug class
  6. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  7. Amorphical Ltd. · 1 shared drug class
  8. Aclaris Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CTI BioPharma:

Cite this brief

Drug Landscape (2026). CTI BioPharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cti-biopharma. Accessed 2026-06-10.

Related